Bedaquiline: current status and future perspectives

J Glob Antimicrob Resist. 2021 Mar 5:S2213-7165(21)00049-7. doi: 10.1016/j.jgar.2021.02.017. Online ahead of print.

ABSTRACT

The development of drug-resistant tuberculosis (TB) is a major global threat worldwide. Based on the World Health Organization reports, it is estimated that more than 500000 new cases of drug-resistant TB happen annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore, new options for TB therapy are mandatory. Bedaquiline (BDQ), a novel anti-TB medicine, has significant minimum inhibitory concentration against both drug-sensitive and drug-resistant TB. Moreover, BDQ was recently approved for MDR-TB therapy. The current narrative review summarizes the available data on BDQ resistance, describes its antimicrobial properties, and provides new perspectives on clinical use of this novel anti-TB agent.

PMID:33684606 | DOI:10.1016/j.jgar.2021.02.017